Journal article

Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia

Barbara de Graaff, Kwang Chien Yee, Philip Clarke, Andrew Palmer

Applied Health Economics and Health Policy | SPRINGER INTERNATIONAL PUBLISHING AG | Published : 2018

Abstract

BACKGROUND: Direct-acting antiviral agents (DAAs) have revolutionised treatment for the hepatitis C virus (HCV). Currently, treatment costs between 20,000 and 80,000 Australian dollars ($A) per patient. The Australian Federal Government provided $A1 billion over 5 years to subsidise these drugs. OBJECTIVE: The aim of this paper was to evaluate the uptake and financial impact of DAA prescribing in Australia. METHODS: We undertook a retrospective analysis of Medicare prescription and expenditure data for March 2016 to August 2017. Prescription numbers and expenditure data were extracted from the Medicare Statistical Reports website. Numbers of prescriptions were converted to per capita..

View full abstract